Member Info for Titania

https://seekingalpha.com/symbol/SYGGF

"The Pfizer Award for Excellence in Interferon and Cytokine Research (formerly the Seymour & Vivian Milstein Award from 1988 – 2020), represents the pinnacle of scientific achievement in interferon and cytokine research since 1988, two years after interferon was first approved for the treatment of hairy cell leukemia. Since that time, it has been widely recognized that interferons and the larger class of cytokines play critical roles in the development and progression of many major diseases including cancer, viral diseases such as hepatitis and influenza, and autoimmune disorders like multiple sclerosis and lupus."

https://cytokinesociety.org/icis-pfizer-award/

For those who haven't already seen Pfizer took over the Seymour and Vivian Milstein Award for Interferon and cytokine research in 2021.

https://stats.oarc.ucla.edu/other/mult-pkg/faq/general/faq-what-are-the-differences-between-one-tailed-and-two-tailed-tests/

Apologies if already posted!

*Sorry (1/48 vs 7/48) SNG001 vs placebo

If only breathless patients were administered SNG001 at that time then could have potentially have been (1/48 vs 7/48) placebo vs SNG001.

"Another CDC study of confirmed cases in the United States found that shortness of breath occurred in about 43 percent of symptomatic adults and 13 percent of symptomatic children."

https://www.healthline.com/health/coronavirus-shortness-of-breath#how-common

A glass half empty! If he only feels relaxed on a boat then he needs to be a bit more upbeat and commercial so that he might be able to buy one himself one day!

"We continue to be excited about the potential of SNG001," Richard Marsden, chief executive of the drug discovery and development company said

From 36 minutes onwards:- Assuming we will get slowly evolving sublineages of Omicron but if we get a curved ball all bets are off and we change!

From 6th September
https://www.youtube.com/watch?v=F2WCaRQGv60
Apologies if already posted.

Exclusion criteria for phase 3 hospital trial:-

"Evidence of ongoing SARS-CoV-2 infection for more than 3 weeks, confirmed by a validated molecular assay or validated antigen assay"

3 weeks seems like a long time to have had Covid before an antiviral treatment is administered given on average breathlessness appears 5 days after the first Covid symptom.

https://clinicaltrials.gov/ct2/show/NCT04732949

"Some research indicates that difficulty breathing occurs, on average, 5 days after the first COVID-19 symptom appears, in people who require hospital care for the disease."

https://www.medicalnewstoday.com/articles/covid-19-and-shortness-of-breath#when-it-occurs

What's the commercial director Richard Hennings doing? We hardly ever hear his name mentioned!
I wish I'd sold when Leonard Licht did. This company feels like its going at space walking speed!

Just sent an email re long covid results will report back if any reply!

"To assess the strength of this signal and identify specific patient populations that might benefit most from treatment, post hoc analyses were performed on groups of patients recognised to be at greater risk of developing severe disease in hospital. These analyses included patients =65 years old, those with co-morbidities associated with worse COVID-19 outcomes, and those who, at baseline, despite receiving low flow oxygen, had clinical signs of compromised respiratory function (defined as oxygen saturation of = 92% or respiratory rate = 21 breaths/min).

These analyses showed stronger treatment effects with SNG001 in these high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. In these patients, who represented approximately one-third of the SPRINTER trial population, SNG001 significantly reduced the risk of progression to severe disease and death compared to placebo by 70% in the Per Protocol population (Odds Ratio (95% Confidence Interval) 0.23 (0.06, 0.98); p=0.046)."

According to an article on the 4th of January in the FT half of people with Long Covid experienced breathlessness!

https://www.politico.eu/article/who-urges-action-as-17m-long-covid-cases-estimated-in-europe-region/

Hoping Synairgen can be part of the answer to this!

"When your immune system first encounters a pathogen or even a perceived threat – such as a vaccine that resembles a virus – it rapidly recruits “B” cells that have the potential to become antibody-producers. Then, any of these “naive” B cell recruits – naive being a technical term used in immunology – that demonstrate an ability to competently attack the invader are put into a boot camp of sorts.

Here, the cells are trained to better recognize and combat the threat. The training period is intense and mistakes are not tolerated; B cells with any discernible potential for misdirected attacks against their host are killed. However, like any training process, this buildup and mobilization takes time – typically a week or two.

So, what happens when the threat is more immediate – when someone is quite literally fighting for their life in an intensive care unit?

Researchers now know that under the stress of severe viral infection with SARS-CoV-2, that training process collapses. Instead, it is replaced by an emergency response in which new recruits with little training are rushed into battle.

Friendly fire is the unfortunate result."

https://science.thewire.in/health/long-covid-autoimmune-disease/

https://www.worldhealthnetwork.global/long-covid-symposium

Synairgen and interferon not mentioned but looks like another interesting event about Long Covid on 15th September.

"Traumakine works by up-regulating CD73, a key organ protective endothelial enzyme that reduces inflammation and prevents vascular leakage."

In 6 months time we we can be bought for highest price over the last twelve months of approx 30p. No move before then but the probability of a move has increased substantially since yesterday!

"To enable a precision medicine strategy through detection of immune and inflammatory biomarkers associated with virus type and disease trajectory."

https://www.southampton.ac.uk/ctu/trialportfolio/listoftrials/universal.page

Sorry re Activ 2